Anixa Biosciences IncANIX

時価総額
$9224.6万
PER
2011年
10月31日
2012年
10月31日
2014年
10月31日
2015年
10月31日
2017年
10月31日
2018年
10月31日
2019年
10月31日
2020年
10月31日
2021年
10月31日
2022年
10月31日
2023年
10月31日
Revenue1947,08549362,5001250,000-512,500-0
Inventor royalties, contingent legal fees, litigation and licensing expenses--1147,67091,451768,410166,250-385,002-0
Research and development expenses (including non-cash share based compensation expenses of $2,037 and $3,635, respectively)32--275,473,4274675
General and administrative expenses (including non-cash share based compensation expenses of $2,698 and $3,117, respectively)-------6776
Total operating costs and expenses6591061512,140,00510141411
Loss from operations-5,028,266-4,134,556-5,044,068-944,759-6,075,584-14,289,058-11,890,005-9,978,202-13,135,692-14-11
Gain on disposal of property and equipment-----45,915---5,447--
Interest income-------33,9232,32201
Interest income-------33,9232,32201
Net loss-----5,008,991-14,243,084-11,818,652-10,092,363-13,127,923-14-10
Net loss-----5,008,991-14,243,084-11,818,652-10,092,363-13,127,923-14-10
Less: Net loss attributable to noncontrolling interest------247,059-171,598-74,008-173,523-0-0
Less: Net loss attributable to noncontrolling interest------247,059-171,598-74,008-173,523-0-0
Net loss attributable to common stockholders-7,378,036-4,252,799-9,606,314-1,379,043-5,008,991-13,996,025-11,818,652-10,018,355-12,954,400-14-10
Net loss attributable to common stockholders-7,378,036-4,252,799-9,606,314-1,379,043-5,008,991-13,996,025-11,818,652-10,018,355-12,954,400-14-10
Basic----------0.450.32
Basic----------0.450.32
Basic----------0.450.32
Diluted----------0.32